SEARCH

SEARCH BY CITATION

References

  • 1
    Andrews PLR, Bailey HE, Hawthorn J, Stables R, Tyers MB. GR38032F, a novel 5-HT3-receptor antagonist, can both abolish emesis induced by cyclophosphamide or radiation in the ferret. Br J Pharmacol 1987;91(Suppl): 417P.
  • 2
    Andrews PRL, Davis CJ. The mechanism of emesis induced by anticancer therapies. In: AndrewsPRL, ed. Emesis in anticancer therapy: Mechanisms and treatment. London : Chapman and Hall Medical, 1993:113161.
  • 3
    Andrews PLR, Hawthorn J. Evidence for an extra-abdominal site of action for the 5-HT3-receptor antagonist BRL24924 in the inhibition of radiation-evoked emesis in the ferret. Neuropharmacology 1987;26:13671370.
  • 1
    . Anonymous:ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729764.
  • 5
    Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000;35:827831.
  • 6
    Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083152.
  • 7
    Betz H. Ligand-gated ion channels in the brain: The amino acid receptor superfamily. Neuron 1990;5:383392.
  • 8
    Boast C, Bartolomeo AC, Morris H, Moyer JA. 5-HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol Learn Mem 1999;71:259271.
  • 9
    Bock M, Sinner B, Gottlicher M, Martin E, Motsch J. Dolasetron prevents postanesthetic shivering. Anesthesiology 1999;91:A1184.
  • 10
    Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiology 1999;90:432436.
  • 11
    Bosek V, Hu P, Robinson LA. Acute myocardial ischemia after administration of ondansetron hydrochloride. Anesthesiology 2000;92:885887.
  • 12
    Bradley PB, Engel G, Feniuk W et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986;25:563576.
  • 13
    Broocks A, Briggs NC, Pigott TA, et al. Behavioral, physiological and neuroendocrine responses in healthy volunteers to μ-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology (Berl) 1997;130:91103.
  • 14
    Bunce KT, Tyers MB. The role of 5-HT in postoperative nausea and vomiting. Br J Anaesth 1992;69 (Suppl 1): 60S62S.
  • 15
    Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988;94:397412.
  • 16
    Castejon AM, Cubeddu LX. Level of punishment determines anticonflict activity of ondansetron in pigeons: Comparison with buspirone and diazepam. Pharmacol Biochem Behav 1998;61:451457.
  • 17
    Chung F, Lane R, Spraggs C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol 1999;16:669677.
  • 18
    Clayton BD, Thomas RE. Nausea and vomiting. In: HerfindalET, ed. Clinical pharmacy and therapeutics. Philadelphia , PA : Williams & Wilkins, 1992:424430.
  • 19
    Costall B, Domeney AM, Gunning SJ, Naylor RJ, Tattershall FD, Tyers MB. GR38032F, a novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol 1988;94:3974l2.
  • 20
    Cunningham RS. 5-HT3 receptor antagonists: A review of pharmacology and clinical efficacy. Oncology Nursing Forum 1997;24:3340.
  • 21
    Doty P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 1994;5:461469.
  • 22
    Fabling JM, Gan TJ, El-Moalem HE, Warner DS, Borel CO. A randomized double-blind comparison of ondansetron, droperidol and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy. Anesth Analg 2000;91:358361.
  • 23
    Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel stndrome by 5-HT3 antagonism (ondansetron). Digestion 1996;57:478483.
  • 24
    Gregory RE, Ettinger DS. 5-HT3-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173189.
  • 25
    Hasler WL. Serotonin receptor physiology: Relation to emesis. Dig Dis Sci 1999;44(Suppl 8): 108S113S.
  • 26
    Hoyer D, Clarke DE, Fozard JR et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157203.
  • 27
    Johnson BA, Ait-Daoud N. Medications to treat alcoholism. Alcohol Res Health 1999;23:99106.
  • 28
    Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berl) 2000;149:327334.
  • 29
    Johnson BA, Roache JD, Javors MA et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000;284:963971.
  • 30
    Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000;14:3340.
  • 31
    Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994;49:610.
  • 32
    King GR, Xiong Z, Douglass S, Ellinwood EH. Long-term blockade of the expression of cocaine sensitizationby ondansetron, a 5-HT3-receptor antagonist. Eur J Pharmacol 2000;394:97101.
  • 33
    King GR, Xiong Z, Ellinwood EH Jr. Blockade of cocaine sensitization and tolerance by the co-administration of ondansetron, a 5-HT3 receptor antagonist, and cocaine. Psychopharmacology (Berl) 1997;130:15965.
  • 34
    Klein RL, Sanna E, McQuilkin SJ, Whiting PJ, Harris RA. Effects of 5-HT3-receptor antagonists on binding and function of mouse and human GABAA receptors. Eur J Pharmacol 1994;268:237246.
  • 35
    Kovac Al. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000;59:213243.
  • 36
    Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: A role for 5-HT3 antagonists Br J Anaesth 1999;82:439441.
  • 37
    Lovinger DM. 5-HT3 receptors and the neural actions of alcohols: An increasingly exciting topic. Neurochem Int 1999;35:12530.
  • 38
    Manullang TR, Viscomi CM, Pace NL. Intrathecal fentanyl is superior to intravenous ondansetron for the prevention of perioperative nausea during cesarean delivery with spinal anesthesia. Anesth Analg 2000;90:11621166.
  • 39
    Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine3 antagonist ondansetron with high dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816821.
  • 40
    Mathew RJ, Wilson WH. Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. Psychiatry Res 1991;40:125134.
  • 41
    Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia Aliment Pharmacol Ther 1996;10:595599.
  • 42
    McBride WJ, Li TK. Animal models of alcoholism: Neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol 1998;12:339369.
  • 43
    McCann UD, Morgan CM, Geraci M, Slate SO, Murphy DL, Post RM. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 1997;17:360369.
  • 44
    Melamed E, Friedberg G, Zoldan J. Psychosis: Impact on the patient and family. Neurology 1999;52:S1416.
  • 45
    Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865870.
  • 46
    Murphy M, Carmichael AJ. Renal itch. Clin Exp Dermatol 2000;25:103106.
  • 47
    Naylor RJ, Inall FC. The physiology and pharmacology of postoperative nausea and vomiting. Anaesthesia 1994;49(Suppl): 25.
  • 48
    Page IH. Serotonin (5-hydroxytryptamine). Physiol Rev 1954;34:563588.
  • 49
    Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: Report on a retrospective analysis of a 5-HT3 regimen and literature review. Support Care Cancer 1999;7:413424.
  • 50
    Pinelli A, Trivulzio S, Tomasoni L. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats. Eur J Pharmacol 1997;340:111119.
  • 51
    Pollard BJ. Pharmacology of neuromuscular blocking drugs. In: HarperNJN, ed. Muscle relaxants in anaesthesia. London : Arnold Edward, 1995:1325.
  • 52
    Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 1990;2:7175.
  • 53
    Rajeeva V, Bhardwaj N, Batra YK, Dhaliwal LK. Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy. Can J Anaesth 1999;46:4044.
  • 54
    Rex A, Voigt JP, Voits M, Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 1998;59:677683.
  • 55
    Roberts LJ, Oates JA. Disorders of vasodilator hormones: The carcinoid syndrome and mastocytosis. In: WilsonJD, ed. Williams text-book of endocrinology. Philadelphia , PA : W. B. Saunders Company, 1992:16191625.
  • 56
    Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3-receptor antagonists: Differences and similarities. Eur J Cancer 1997;33:13641370.
  • 57
    Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharmacol 1998;18:121131.
  • 58
    Roychoudhury M, Kulkarni SK. Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. Methods Find Exp Clin Pharmacol 1997;19:107111.
  • 59
    Russell D, Kenny GNC. 5-HT3 antagonists in postoperative nausea and vomiting. Br J Anaesth 1992;69:63S68S.
  • 60
    Schreiber R, Melon C, De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl) 1998;135:383391.
  • 61
    Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry 2000;157:287289.
  • 62
    Sniadach MS, Alberts MS. A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy. Anesth Anal 1997;85:797800.
  • 63
    Stables R, Andrews PLR, Bailey HE, et al. Antiemetic properties of the 5-HT3-receptor antagonist, GR38032F. Cancer Treat Rev 1987;14:333336.
  • 64
    Sussman G, Shurman J, Creed MR, Larsen LS, Ferrer-Beecher T, Noll D. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther 1999;21:12161227.
  • 65
    Toren P, Laor N, Cohen DJ, Wolmer L, Weizman A. Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 1999;14:373376.
  • 66
    Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. Br Med J 1997;314:10881092.
  • 67
    Tramer MR, Phillips C, Reynolds DG, McQuay HJ, Moore RA. Cost-effectiveness of ondansetron for postoperative nausea and vomiting. Anaesthesia 1999;54:226234.
  • 68
    Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT3 receptor research. Eur J Pharmacol 1990;188:301312.
  • 69
    Watcha MF. The cost-effective management of postoperative nausea and vomiting. Anesthesiology 2000;92:931933.
  • 70
    Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773794.
  • 71
    Ye JH, Hunt T, Wu WH, McArdle JJ. Ondansetron modulates GABAA current of rat central nervous system neurons. Eur J Pharmacol 1997;337:8794.
  • 72
    Ye JH, Mui WC, Ren J, Hunt TE, Wu WH, Zbuzek VK. Ondansetron exhibits the properties of a local anesthetic. Anesth Analg 1997;85:11161121.
  • 73
    Ye JH, Schaefer R, Wu WH, Liu PH, Zbuzek VK, McArdle JJ. Inhibitory effect of ondansetron on glycine response of dissociated rat hippocampal neurons. J Pharmacol Exp Ther 1999;290:104111.
  • 74
    Yeh HM, Chen LK, Lin CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2000;91:172175.
  • 2
    . Zofran (ondansetron hydrochloride) and clinical pharmacology. In: Zofran Product Information, released by Glaxo Wellcome, Research Triangle Park , NC . October, 1999.
  • 3
    . Zofran (ondansetron hydrochloride) and dosage adjustment in patients with hepatic dysfunction. In: Zofran Product Information, released by Glaxo Wellcome, Research Triangle Park , NC . October 1999.